论文部分内容阅读
目的研究乳腺浸润性导管癌中PTEN蛋白表达与乳腺癌不同的临床病理因素、TNM分期的关系及其临床意义。方法采用免疫组织化学SP法,对32例乳腺浸润性导管癌组织中PTEN蛋白的表达水平进行检测。结果正常乳腺组织中PTEN表达阳性,32例乳腺癌中有13例PTEN阴性表达(41%),其中8例雌激素受体(ER)、孕激素受体(PR)阴性(61.5%),而19例PTEN阳性表达标本中仅4例ER、PR均为阴性(21.1%)。有腋淋巴结转移的乳腺浸润性导管癌组织中PTEN表达水平显著低于无腋淋巴结转移的乳腺浸润性导管癌组织(P<0.001);ER阴性者PTEN表达水平明显低于ER阳性者(P<0.05),PTEN表达水平与患者年龄、肿瘤大小、孕激素水平及临床分期无关,但随临床分期的增高,PTEN表达水平呈下降趋势。结论乳腺癌组织中PTEN蛋白失表达与腋淋巴结转移及雌激素阴性水平密切相关。
Objective To study the clinicopathological significance and clinicopathologic significance of PTEN protein expression in breast invasive ductal carcinoma and breast cancer. Methods Immunohistochemical SP method was used to detect the expression of PTEN protein in 32 cases of invasive ductal carcinoma of the breast. Results The positive expression of PTEN was found in normal breast tissue. Thirteen of 32 breast cancer samples were positive for PTEN (41%), of which 8 were negative for estrogen receptor (ER) and negative for progesterone receptor (PR) Of the 19 PTEN positive samples, only 4 cases had ER and PR negative (21.1%). The expression of PTEN in invasive ductal carcinoma of the breast with axillary lymph node metastasis was significantly lower than that in the invasive ductal carcinoma without axillary lymph node metastasis (P <0.001). The expression of PTEN in ER-negative was significantly lower than that in ER-positive (P < 0.05). The expression level of PTEN was not related to the patient’s age, tumor size, progesterone level and clinical stage. However, with the increase of clinical stage, the expression level of PTEN showed a decreasing trend. Conclusion The loss of PTEN protein expression in breast cancer is closely related to axillary lymph node metastasis and estrogen-negative levels.